Aratana Therapeutics

Aratana Therapeutics is a pioneer in pet therapeutics focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Its goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. The Сompany's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.


Company Growth (employees)
Type
Public
HQ
Leawood, US
Founded
2010
Size (employees)
56 (est)
Aratana Therapeutics was founded in 2010 and is headquartered in Leawood, US

Key People at Aratana Therapeutics

Louise MawHinney

Louise MawHinney

CFO
Ernst Heinen

Ernst Heinen

Head of Drug Evaluation and Development
John Ayers

John Ayers

General Counsel & Secretary
James Miller

James Miller

Controller
Marie-Paul Lachaud

Marie-Paul Lachaud

Head of Business & Product Development Europe

Aratana Therapeutics Office Locations

Aratana Therapeutics has offices in Leawood, San Diego and Leuven
Leawood, US (HQ)
11400 Tomahawk Creek Pkwy, Suite 340
Leuven, BE
1 Ambachtenlaan
San Diego, US
10451 Roselle St, Suite 200A

Aratana Therapeutics Data and Metrics

Aratana Therapeutics Financial Metrics

Aratana Therapeutics's revenue was reported to be $3.8 m in Q1, 2017
USD

Revenue (Q1, 2017)

3.8 m

Gross profit (Q1, 2017)

701 k

Gross profit margin (Q1, 2017), %

18%

Net income (Q1, 2017)

(12.6 m)

EBIT (Q1, 2017)

(11.8 m)

Market capitalization (15-Aug-2017)

221.5 m

Cash (31-Mar-2017)

67.5 m
Aratana Therapeutics's current market capitalization is $221.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

123 k767 k678 k38.6 m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

108 k365 k3.1 m

Gross profit

15 k313 k35.4 m

Gross profit Margin, %

12%46%92%

Operating expense total

42 m42 m89.8 m69.4 m

EBIT

(41.9 m)(41.6 m)(89.5 m)(30.8 m)

EBIT margin, %

(34102%)(5425%)(13200%)(80%)

Interest expense

432 k1.6 m3.4 m

Interest income

75 k189 k385 k

Pre tax profit

(19.7 m)(85.8 m)(33.6 m)

Income tax expense

15.5 m1.7 m1.7 m

Net Income

(26.2 m)(38.8 m)(84.1 m)(33.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

300 k43 k156 k230 k229 k172 k38 m40 k3.8 m

Cost of goods sold

110 k109 k138 k19 k1.7 m286 k3.1 m

Gross profit

46 k121 k91 k153 k36.3 m(246 k)701 k

Gross profit Margin, %

29%53%40%89%95%(615%)18%

R&D expense

4.3 m6.1 m6.2 m6.1 m6.2 m10.7 m5.3 m5.3 m4.7 m

General and administrative expense

4.4 m3.9 m4.2 m4.9 m5 m6.6 m6.1 m6.9 m7.5 m

Operating expense total

8.7 m10 m10.4 m11 m11.2 m17.3 m11.5 m12.3 m12.1 m

EBIT

(9.5 m)(10.5 m)(10.9 m)(11.3 m)(55 m)(17.3 m)22 m(12.6 m)(11.8 m)

EBIT margin, %

(3168%)(24488%)(6963%)(4933%)(24021%)(10035%)58%(31535%)(312%)

Interest expense

(218 k)(222 k)(218 k)(217 k)(226 k)(849 k)(846 k)(859 k)(860 k)

Interest income

13 k31 k71 k43 k33 k77 k83 k116 k85 k

Pre tax profit

(9.6 m)(10.7 m)(9 m)(8.3 m)(55.2 m)(18.1 m)21.2 m(13.4 m)

Income tax expense

335 k601 k271 k360 k758 k

Net Income

(18.4 m)(28.6 m)(8.8 m)(8 m)(71.2 m)(18.1 m)3.1 m(10.2 m)(12.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

41.1 m9.8 m26.8 m87.3 m

Accounts Receivable

352 k60 k87 k

Inventories

274 k427 k1.3 m11.1 m

Current Assets

48.5 m99.9 m89 m101.5 m

PP&E

98 k620 k2.6 m1.9 m

Goodwill

20.8 m41.4 m39.8 m39.4 m

Total Assets

115.5 m207.9 m147.1 m151.4 m

Accounts Payable

2.3 m1.5 m1.4 m7.4 m

Current Liabilities

16.9 m9.5 m5.7 m34.7 m

Total Liabilities

61 m

Additional Paid-in Capital

112.5 m255 m263.9 m286.9 m

Retained Earnings

(68 m)(152 m)(185.6 m)

Total Equity

86 m181.8 m101.6 m90.4 m

Financial Leverage

1.3 x1.1 x1.4 x1.7 x
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

56.8 m30.2 m12.6 m13.5 m13.8 m108.8 m100.8 m67.5 m

Accounts Receivable

90 k115 k148 k134 k11 k17 k15 k3.5 m

Inventories

203 k645 k882 k1.2 m2.4 m2.6 m5.6 m9.1 m

Current Assets

110.5 m89.4 m85.7 m75.3 m77.1 m113.7 m110.9 m81.9 m

PP&E

741 k614 k1.6 m2.3 m2.4 m2.3 m2.1 m1.6 m

Goodwill

37.1 m39.6 m40.2 m40.2 m40.5 m40 m40.3 m39.6 m

Total Assets

221.3 m193.3 m186.9 m133.4 m136 m168.9 m167.3 m134.7 m

Accounts Payable

1.9 m2.1 m1.7 m1.2 m6.4 m7.3 m5.1 m1.2 m

Current Liabilities

9.9 m5.7 m20.9 m5.4 m8.6 m21.1 m21.4 m30.7 m

Additional Paid-in Capital

253.1 m257.4 m259.5 m261.8 m266.2 m268.4 m283 m290.1 m

Retained Earnings

(55.1 m)(76.7 m)(84.7 m)(139.2 m)(170.1 m)(148.9 m)(162.3 m)(198.4 m)

Total Equity

193 m171.5 m165.1 m113 m86.9 m109.6 m111.2 m81.1 m

Financial Leverage

1.1 x1.1 x1.1 x1.2 x1.6 x1.5 x1.5 x1.7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.3 m)(38.8 m)(84.1 m)(33.6 m)

Depreciation and Amortization

395 k2 m1.8 m379 k

Accounts Receivable

(102 k)281 k(27 k)

Inventories

(372 k)(879 k)(15 m)

Accounts Payable

1.5 m(1.1 m)(117 k)6.2 m

Cash From Operating Activities

(16.2 m)(32.2 m)(38.5 m)(11.3 m)

Cash From Investing Activities

(29.2 m)(100.1 m)33.7 m57.3 m

Cash From Financing Activities

72.5 m101 m21.9 m14.6 m

Interest Paid

357 k942 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(18.4 m)(28.6 m)(8.8 m)(8 m)(71.2 m)(18.1 m)3.1 m(10.2 m)(12.6 m)

Depreciation and Amortization

1.2 m1.9 m520 k1.1 m1.6 m244 k493 k738 k392 k

Accounts Receivable

(116 k)174 k227 k194 k208 k49 k43 k45 k(3.5 m)

Inventories

(69 k)(148 k)(218 k)(455 k)(746 k)(1 m)(2.8 m)(5.8 m)2.1 m

Accounts Payable

(1.7 m)(763 k)630 k213 k(274 k)5 m5.9 m3.7 m(6.2 m)

Cash From Operating Activities

(15.9 m)(22.8 m)(9 m)(17.8 m)(28.1 m)(13.4 m)23.3 m5.2 m(18.4 m)

Cash From Investing Activities

(13.1 m)32.5 m23.6 m34.6 m442 k58.7 m56.9 m(2.5 m)

Cash From Financing Activities

56.2 m101 m(3 m)(3 m)(2.7 m)(3 m)1 k11.9 m1.2 m

Interest Paid

413 k584 k206 k415 k628 k721 k1.4 m2.2 m733 k
USDY, 2017

Revenue/Employee

67.8 k

Financial Leverage

1.7 x

Aratana Therapeutics Market Value History

Traffic Overview of Aratana Therapeutics

Aratana Therapeutics Online and Social Media Presence

Aratana Therapeutics Company Life and Culture

You may also be interested in